S 3792 · 115th Congress 2017–2019, ended

Preserve Access to Affordable Generics and Biosimilars Act

Latest action · Dec 19, 2018 Read twice and referred to the Committee on the Judiciary.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedDec 19, 2018
  2. Passed SenateNot reached
  3. Passed HouseNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Preserve Access to Affordable Generics and Biosimilars Act

This bill amends the Federal Trade Commission Act to authorize the Federal Trade Commission to initiate proceedings against parties to any agreement resolving or settling a patent infringement claim in connection with the sale of a drug or biological product. Such an agreement, with specified exceptions, is presumed to have anticompetitive effects and violates this bill if the filer of an abbreviated new drug (generic) application or a biosimilar biological product application: (1) receives anything of value; and (2) agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biosimilar biological product for any period of time.

Cosponsors 1

Members who signed on, in the order they did. All signed on Dec 19, 2018.

SeatCosponsorSigned on
R-IAChuck GrassleyOriginalDec 19, 2018

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
SenateJudiciary Committee
Referred Dec 19, 2018

Actions 2

Everything that happened, newest first.

  1. Dec 19, 2018Introduced in Senate
  2. Dec 19, 2018Read twice and referred to the Committee on the Judiciary.

Related bills 1

Companion bills and other measures the record links to this one.

BillTitleRelationshipLatest action
S 124Preserve Access to Affordable Generics ActRelated billJan 12, 2017

Titles 2

Every title it has carried, official and short, at each stage.

Official Title as Introduced
A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufactures from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
Short Titles as Introduced
Preserve Access to Affordable Generics and Biosimilars Act

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Dec 19, 2018Introduced in Senate

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.